Sylwia Szczepara

Dr. Sylwia Szczepara

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2026 in JACC: Case Reports
Verified
Journal Article
Open access
SSSylwia Szczepara
Sylwia Szczepara
KPKlaudia Pacia
Klaudia Pacia
JSJoanna Szachowicz-Jaworska
Joanna Szachowicz-Jaworska
PPPiotr Podolec
Piotr Podolec
GKGrzegorz Kopeć
Grzegorz Kopeć
MKMonika Komar
Monika Komar
Fabry disease in women may progress silently, and normal baseline cardiac magnetic resonance (CMR) does not exclude subsequent cardiac involvement. A 39-year-old woman with genetically confirmed Fabry disease and no prior disease-specific therapy had normal biomarkers, renal function, echocardiography, and CMR in 2022. In 2025, she developed acroparesthesias, reduced sweating, tinnitus, and constipation. Echocardiography showed increased left ventricular wall thickness. Follow-up CMR demonstrated preserved left ventricular ejection fraction, basal septal thickening to 14 mm, low native T1 (874 ms), extracellular volume of 26.9%, and new midwall late gadolinium enhancement. Enzyme replacement therapy was initiated. Women with Fabry disease may develop structural cardiac involvement despite preserved systolic function and normal cardiac biomarkers, supporting individualized serial multimodality surveillance. Preserved left ventricular ejection fraction and normal cardiac biomarkers do not exclude Fabry cardiomyopathy; interval echocardiographic changes or symptoms should prompt repeat CMR and reassessment for disease-specific therapy.

1 September 2025 in Medical Sciences
Verified
Journal Article
Open access
PDF file
SSSylwia Szczepara
Sylwia Szczepara
KPKlaudia Pacia
Klaudia Pacia
KTKatarzyna Trojanowicz
Katarzyna Trojanowicz
KBKlaudia Bielecka
Klaudia Bielecka
MTMichał Tworek
Michał Tworek
MKMonika Komar
Monika Komar
Objective: Fabry disease (FD) is a rare, X-linked lysosomal storage disorder resulting from deficient α-galactosidase A activity, which can manifest as left ventricular hypertrophy (LVH). We aimed to assess the prevalence of FD in an unselected cohort of patients with unexplained LVH. Methods and results: We screened 202 unrelated adults with LVH using enzymatic assays for α-galactosidase A in dried blood spots. Patients with low activity underwent GLA gene sequencing. Echocardiographic parameters were evaluated according to ESC guidelines. FD was diagnosed in 4 women (2%), each carrying distinct pathogenic GLA mutations. All affected individuals showed normal or borderline enzyme activity. Cardiac, renal, or neurological symptoms were observed variably among patients. Echocardiographic findings revealed slightly lower wall thickness and preserved systolic function in FD patients compared to those without FD. Cascade genetic screening identified 16 additional family members with the same mutations. One patient (0.5%) was incidentally diagnosed with Gaucher disease based on syndromic features and enzymatic testing. Conclusions: FD was identified in 2% of patients with unexplained LVH, who were females. Enzyme-based screening followed by targeted genetic testing is a cost-effective strategy for FD detection. Early diagnosis is essential for prompt treatment and family counselling, underscoring the importance of routine FD screening in patients with LVH of unclear aetiology. Our findings support the use of targeted screening for Fabry disease in patients with LVH and systemic features, and highlight the potential to identify other lysosomal disorders in selected cases.

Verified
Journal Article
Open access
PDF file
MTMichał Tworek
Michał Tworek
KTKatarzyna Trojanowicz
Katarzyna Trojanowicz
ZSZuzanna Sachajko
Zuzanna Sachajko
MKMonika Kowalik
Monika Kowalik
KPKlaudia Pacia
Klaudia Pacia
MKMonika Komar
Monika Komar
Background: Patent foramen ovale (PFO) is associated with cryptogenic stroke, but mechanisms beyond paradoxical embolism remain unclear. Inflammation, fibrosis-related remodeling, and nitrosative stress may contribute to vascular vulnerability in these patients. The aim of this study was to evaluate inflammatory, fibrotic, and nitrosative biomarker profiles in patients with PFO and prior cryptogenic stroke and to determine whether these patients exhibit coupled inflammatory fibrotic nitrosative activation. Methods: This prospective, observational, single-center study included 92 patients aged <55 years with PFO and prior cryptogenic stroke and 56 age-matched controls without PFO and cerebrovascular events. Circulating interleukin-18 (IL-18), galectin-3, and 3-nitrotyrosine (3-NT) levels were measured using ELISA assays. Correlation and linear regression analyses were performed. Results: Compared with controls, patients with PFO had higher galectin-3 (11.87 vs. 10.36 ng/mL; p = 0.015), IL-18 (268.0 vs. 121.0 pg/mL; p < 0.001), and 3-NT (48.5 vs. 41.8 ng/mL; p = 0.046). Significant correlations were observed between IL-18 and galectin-3 (r = 0.565), IL-18 and 3-NT (r = 0.425), and galectin-3 and 3-NT (r = 0.292) (all p ≤ 0.002). Conclusions: Patients with PFO and prior cryptogenic stroke exhibit a distinct biomarker profile consistent with coupled inflammatory–fibrotic–nitrosative activation, suggesting a potential non-mechanical component of stroke susceptibility.